GW Pharmaceuticals plc (GWP) - Financial and Strategic SWOT Analysis Review

Summary

GW Pharmaceuticals plc (GW Pharmaceuticals) is a pharmaceutical company. It focuses on research, development and commercialization of cannabinoid prescription and botanical drugs. The company’s lead product, Sativex is administered for relief from neuropathic pain in multiple sclerosis (MS) and also as an adjunct to analgesic treatment in adult patients with advanced cancer. It is also developing products for the treatment of diabetes/metabolic syndrome, inflammation, cancer, epilepsy and psychiatric illness.

GW Pharmaceuticals plc Key Recent Developments

Nov 28, 2012: GW Pharma Reports Fiscal 2012 Preliminary Results
Oct 01, 2012: GW Pharma Appoints Christopher John Tovey As COO
Sep 12, 2012: New Cannabis Discovery Could Lead To Better Treatments For Epilepsy, New Study Says
May 22, 2012: GW Pharma Reports Revenue Of £11.1m In H1 Fiscal 2012
Mar 08, 2012: GW Pharma Names Vincenzo Di Marzo To Direct Its Global Pre-clinical Research ProgramGDPH56947FSA

This comprehensive SWOT profile of GW Pharmaceuticals plc provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. SHOW LESS READ MORE >

List of Tables
List of Figures
Section 1 - About the Company
GW Pharmaceuticals plc - Key Facts
GW Pharmaceuticals plc - Key Employees
GW Pharmaceuticals plc - Key Employee Biographies
GW Pharmaceuticals plc - Major Products and Services
GW Pharmaceuticals plc - Pharmaceutical Pipeline Products Data
GW Pharmaceuticals plc, Pipeline Products by Therapy Area
GW Pharmaceuticals plc, Pipeline Products by Development Phase
GW Pharmaceuticals plc - History
GW Pharmaceuticals plc - Company Statement
GW Pharmaceuticals plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
GW Pharmaceuticals plc - Business Description
GW Pharmaceuticals plc - Corporate Strategy
GW Pharmaceuticals plc - SWOT Analysis
SWOT Analysis - Overview
GW Pharmaceuticals plc - Strengths
Strength - Focused Research and Development
Strength - Licensing Agreements
Strength - Global Reach
Strength - Strong Patent Portfolio
GW Pharmaceuticals plc - Weaknesses
Weakness - Declining Revenues in a particular region
GW Pharmaceuticals plc - Opportunities
Opportunity - Market Potential: Multiple Sclerosis
Opportunity - Market Potential: Oncology
Opportunity - Pharmerging Markets
GW Pharmaceuticals plc - Threats
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Threat - Competitive Landscape
GW Pharmaceuticals plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
GW Pharmaceuticals plc, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
GW Pharmaceuticals plc, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
GW Pharmaceuticals plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
GW Pharmaceuticals plc, Recent Developments
Nov 28, 2012: GW Pharma Reports Fiscal 2012 Preliminary Results
Oct 01, 2012: GW Pharma Appoints Christopher John Tovey As COO
Sep 12, 2012: New Cannabis Discovery Could Lead To Better Treatments For Epilepsy, New Study Says
May 22, 2012: GW Pharma Reports Revenue Of £11.1m In H1 Fiscal 2012
Mar 08, 2012: GW Pharma Names Vincenzo Di Marzo To Direct Its Global Pre-clinical Research Program
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
GW Pharmaceuticals plc, Key Facts
GW Pharmaceuticals plc, Key Employees
GW Pharmaceuticals plc, Key Employee Biographies
GW Pharmaceuticals plc, Major Products and Services
GW Pharmaceuticals plc, Number of Pipeline Products by Therapy Area
GW Pharmaceuticals plc, Number of Pipeline Products by Development Stage
GW Pharmaceuticals plc, Pipeline Products By Therapy Area and Development Phase
GW Pharmaceuticals plc, History
GW Pharmaceuticals plc, Other Locations
GW Pharmaceuticals plc, Subsidiaries
GW Pharmaceuticals plc, Key Competitors
GW Pharmaceuticals plc, Ratios based on current share price
GW Pharmaceuticals plc, Annual Ratios
GW Pharmaceuticals plc, Interim Ratios
GW Pharmaceuticals plc, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
GW Pharmaceuticals plc, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
GW Pharmaceuticals plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
GW Pharmaceuticals plc, Pipeline Products by Therapy Area
GW Pharmaceuticals plc, Pipeline Products by Development Phase
GW Pharmaceuticals plc, Performance Chart (2008 - 2012)
GW Pharmaceuticals plc, Ratio Charts
GW Pharmaceuticals plc, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
GW Pharmaceuticals plc, Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Tyrian Diagnostics Limited
Evotec Aktiengesellschaft
Oxford BioMedica plc
Ark Therapeutics Group plc
Alizyme plc